What CVS Caremark does

CVS Caremark (legal entity Caremark L.L.C.) is a vertically integrated pharmacy benefits manager (PBM) and wholly owned subsidiary of CVS Health Corporation (NYSE: CVS), serving approximately 88-100 million members across commercial, Medicare Part D, and Medicaid segments. Founded as Caremark in 1979 by James M. Sweeney to pioneer home infusion therapy, the company was acquired by CVS in 1996 and re-formed as CVS Caremark Corporation in 2007 following CVS's acquisition of Caremark Rx. It is one of three PBMs — alongside Express Scripts and OptumRx — that collectively control approximately 79-80% of the U.S. prescription drug market and manage benefits for approximately 270 million people.

CVS Caremark operates a vertically integrated PBM technology stack spanning AI-assisted prior authorization (processing 16.4 million requests in 2025), electronic prior authorization via CoverMyMeds and Surescripts partnerships, mail-service pharmacy dispensing from Wilkes-Barre PA, and specialty pharmacy operations from Mount Prospect IL, backed by integrations with Salesforce Agentforce Health, Microsoft Azure, Databricks, and Google Cloud. The core member-facing platform includes the caremark.com web portal, mobile app, and tools for prescription management, drug cost checking, refills, pharmacy locator, and savings opportunities. Add-on modules include the CVS Weight Management Program (available to 3 million+ members as of February 2025 with 15%+ average weight loss and up to 26% lower GLP-1 spending), TrueCost drug-level pricing model, and private-label biosimilar distribution partnerships with Samsung Bioepis.

Revenue is generated through enterprise PBM contracts with plan sponsors (employers, health plans, government payers) via managed services fees, historically augmented by manufacturer rebate retention and spread pricing now under federal reform pressure. The company reaches members through CVS Pharmacy's 9,000+ retail locations, a 68,000+ pharmacy network, CVS Specialty, and CVS Caremark Mail Service Pharmacy. CVS Caremark is embedded in CVS Health's broader vertically integrated platform alongside Aetna (health insurance), Oak Street Health (primary care), and Signify Health (in-home evaluation), enabling unified member data and integrated care coordination cited as delivering 3.7% lower medical costs versus disaggregated PBM models.

Name

CVS Caremark

Legal name

Caremark L.L.C.

Website

https://caremark.com

Company type

Public

Founded year

1979

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

CVS Caremark is a top-three U.S. pharmacy benefits manager (PBM) and subsidiary of CVS Health, serving approximately 88-100 million members across commercial, Medicare Part D, and Medicaid plans through a vertically integrated platform spanning AI-assisted prior authorization, mail-service and specialty pharmacy, and a 68,000+ pharmacy network.

Ownership category

akta.pro rank

Product category

Pharmacy Benefit Management

NAICS

Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)

SIC

Hospital & Medical Service Plans (6324)

akta.pro primary industry

Pharmacy Benefit Management (PBM) & Pharmacy Network Administration (HLAFALAI)

Keywords

• Pharmacy benefit management
• Prescription drug coverage
• Mail order pharmacy
• Specialty pharmacy services
• Formulary management

Headquarters

HQ city

Woonsocket

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Integrated PBM Service Fees: CVS Caremark earns administrative and service fees from plan sponsors for managing prescription drug benefits across commercial, Medicare Part D, and Medicaid lives. The integrated model delivers cost containment, clinical outcomes, member experience, and operational efficiency bundled for clients.
2. Rebate Retention and Spread Pricing: CVS Caremark, along with the other 'Big Three' PBMs, has historically earned revenue through manufacturer rebate retention and spread pricing (charging employers up to 50 times more than Cost Plus Drugs prices for identical drugs), practices now under federal scrutiny and reform.
3. Mail Service Pharmacy Dispensing: Revenue from CVS Caremark Mail Service Pharmacy (NCPDP ID: 0322038, Wilkes-Barre, PA) dispensing 90-day supplies of maintenance medications to plan members, with no-cost shipping.
4. Specialty Pharmacy Dispensing: Revenue from CVS Specialty (NCPDP ID 1466033, Mount Prospect, IL) dispensing high-cost specialty medications and providing clinical support services for complex conditions.
5. Affordable Access Programs and Bridge Programs: Revenue captured through manufacturer-funded affordability programs such as the Medicare GLP-1 Bridge program, enabling $25/month commercial and $50/month Part D access to GLP-1 drugs like Zepbound and Foundayo.
6. Private-Label Biosimilar Distribution: Revenue from CVS Caremark's private-label distribution of biosimilars such as OSPOMYV (in partnership with Samsung Bioepis) and Stoboclo, leveraging PBM formulary control to capture margin on biosimilar uptake.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

CVS Caremark is a pharmacy benefit manager (PBM) that administers prescription drug benefit plans for approximately 88-100 million members across commercial, Medicare Part D, and Medicaid lives. It manages prescription costs through formulary design, prior authorization, and mail-service and specialty pharmacy dispensing via a nationwide network of more than 68,000 retail pharmacies and its own mail-order and specialty operations.

Product overview

CVS Caremark is a single unified Pharmacy Benefit Management (PBM) platform operating as the prescription benefits arm of CVS Health, serving more than 100 million members through a nationwide network of more than 68,000 retail pharmacies and its own CVS Caremark Mail Service Pharmacy and CVS Specialty operations. The platform is anchored by the caremark.com member portal (with member-facing tools including the Check Drug Cost and Coverage, Drug Savings Opportunities, Find a Pharmacy, and Easy Refill/Automatic Refill Program features), the Client Care Access (CCA) Portal for plan sponsors, and the Electronic Prior Authorization (ePA) workflow integrated with CoverMyMeds and Surescripts. Building on this core, CVS Caremark offers several add-on modules and branded programs: the CVS Weight Management Program (clinical support paired with anti-obesity medications for plan members), the TrueCost drug-level pricing model (transitioning PBM contracts toward transparent net-cost pricing away from spread pricing), private-label biosimilars (including the Ospomyv partnership with Samsung Bioepis), and an AI-powered call center experience via Salesforce Agentforce Health spanning Aetna and CVS Caremark operations. Together the core PBM platform, member-facing digital tools, mail and specialty pharmacy operations, formulary programs, and emerging AI/true-cost modules form an integrated prescription benefit offering tied to CVS Health's vertically integrated retail pharmacy, health insurance (Aetna), and clinical care assets.

Differentiator

Problem solved

Functional benefit

Brands

• CVS Specialty: Specialty pharmacy service for complex and high-cost medications, accessible through the CVS Caremark platform.
• Rx Delivery by Mail / CVS Caremark Mail Service Pharmacy

Products and services

• CVS Caremark Pharmacy Benefit Management
• CVS Caremark Mail Service Pharmacy
• CVS Specialty
• CVS Weight Management Program
• Electronic Prior Authorization (ePA)
• Client Care Access (CCA) Portal
• CVS Caremark TrueCost
• CVS Caremark Private-Label Biosimilars
• Salesforce Agentforce Health AI Call Center (CVS Caremark Deployment)

Quantifiable outcome

• $1.5 billion in gross biosimilar savings delivered to customers and members
• +7 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability8 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• SalesforcecoreTechnology or Integration · 28 May 2026CVS Health is deploying Salesforce Agentforce Health, an AI-powered call center solution, across its Aetna health insurance and CVS Caremark prescription plan management operations. AI agents provide real-time insights to call center associates, enabling them to view complete member health profiles across CVS Health businesses to resolve inquiries in a single interaction.
• Eli LillycoreStrategic or Co-development Partner · 28 May 2026Formulary coverage agreement with CVS Caremark to reintroduce Zepbound (tirzepatide) to commercial formularies and remove new-to-market block on Foundayo (orforglipron) by October 2026. Includes active negotiation with Eli Lilly to improve affordability and access for approximately 88 million members, with eligible commercially covered patients able to access both medicines for as little as $25 per month and Medicare Part D patients $50 per month through the Medicare GLP-1 Bridge program.
• Google CloudcoreStrategic or Co-development Partner · 15 May 2026Health100 partnership announced as part of CVS Health's key business updates including CVS Caremark formulary changes favoring biosimilars over Stelara, a new smaller pharmacy format, and a Health100 partnership with Google Cloud.
• Samsung BioepiscoreStrategic or Co-development Partner · 23 April 2026Private-label biosimilar partnership with CVS Caremark for the OSPOMYV biosimilar (osteoporosis). Biosimilar was added to CVS Caremark national commercial template formularies effective April 1, 2026, replacing Prolia. Samsung Bioepis also expanded its development partnership with Sandoz for up to five biosimilar candidates and initiated Phase 1 trials for a novel ADC candidate.
• SandozminorStrategic or Co-development Partner · 23 April 2026Samsung Bioepis expanded its development partnership with Sandoz for up to five biosimilar candidates; Samsung Bioepis itself has a private-label partnership with CVS Caremark for OSPOMYV biosimilar, indirectly linking Sandoz to the CVS Caremark biosimilar ecosystem.
• CoverMyMedscoreTechnology or Integration · 1 January 2026CVS Caremark has partnered with CoverMyMeds to provide electronic prior authorization (ePA) submission through both a web-based portal and EHR integration. The integration enables automated decisioning, sometimes in less than 6 seconds, and operates 2-3 times faster than phone or fax.
• SurescriptscoreTechnology or Integration · 1 January 2026CVS Caremark has partnered with Surescripts to provide electronic prior authorization (ePA) submission through both a web-based portal and EHR integration, enabling automated decisioning that is 2-3 times faster than phone or fax.
• Novo NordiskcoreStrategic or Co-development Partner · 5 May 2025Prior formulary arrangement giving Wegovy preferential status among GLP-1 obesity medications on CVS Caremark preferred formularies affecting 90 million members. The arrangement was reversed in May 2026 when CVS Caremark added Eli Lilly's Zepbound and Foundayo to its preferred formularies.
• MicroStrategy IncorporatedcoreTechnology or IntegrationPer the CVS Caremark Client Care Access Terms of Use, the Applications and/or Services include or require the use of products licensed by CVS Caremark from MicroStrategy Incorporated. Users must comply with applicable MicroStrategy licensing terms.
• Amgen (Prolia / biosimilar manufacturer)minorOEM/ Whitelabel/ Licensing PartnerEffective April 1, 2026, CVS Caremark added osteoporosis biosimilars Ospomyv and Stoboclo along with generic teriparatide medications Bonsity and Tymlos to its major national commercial template formularies, replacing Prolia and Forteo.
• Eli Lilly (Forteo / teriparatide)minorOEM/ Whitelabel/ Licensing PartnerEffective April 1, 2026, CVS Caremark added generic teriparatide medications Bonsity and Tymlos (Eli Lilly Forteo generics) to its major national commercial template formularies.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Express Scripts (now HCSC): One of the Big 3 PBMs alongside CVS Caremark and OptumRx, formerly owned by Cigna and sold to Health Care Service Corporation (HCSC) in 2025; directly comparable PBM serving tens of millions of members with the same formulary/rebate/spread-pricing economics that have drawn identical FTC insulin-pricing scrutiny.
• OptumRx (UnitedHealth Group): The third Big 3 PBM and the largest by scale, embedded within UnitedHealth Group's Optum services platform; CVS Caremark's most direct structural competitor given similar vertically integrated payer-PBM-provider positioning and identical exposure to federal insulin-pricing and rebate-aggregation investigations.
• Prime Therapeutics: Independent PBM owned by a consortium of Blue Cross Blue Shield plans; competes with CVS Caremark for health-plan PBM contracts with a focus on transparent pass-through pricing — directly comparable as a non-vertically-integrated alternative that benefits from the same reform narrative pressuring spread-pricing PBMs.
• Humana Pharmacy Solutions: PBM arm of Humana serving Medicare Advantage and Part D members; competes with CVS Caremark's Medicare Part D segment with similar vertical payer-PBM integration, making it a direct comparable for senior-population formulary management and MA-PD contract economics.
• Magellan Rx Management (Centene): PBM and specialty pharmacy manager owned by Centene Corporation; competes with CVS Caremark primarily in Medicaid managed care and government-program PBM contracts, overlapping on specialty drug management and rebate aggregation services.

Emerging players

• MedImpact Healthcare Systems: Independent, pharmacist-founded PBM competing with CVS Caremark on transparent, pass-through pricing for health plans and employers; a relevant emerging alternative whose transparent-pricing positioning parallels CVS Caremark's TrueCost transition and benefits from the same industry reform tailwinds.
• Navitus Health Solutions: Mid-sized transparent PBM owned by SSM Health and Costco; competes with CVS Caremark on pass-through pricing for employer and health-plan clients, and is frequently cited as a credible alternative to the Big 3 model — directly relevant to CVS Caremark's contract-retention risk.
• Amazon Pharmacy (PillPack): Direct-to-consumer mail-order and PBM-adjacent pharmacy offering from Amazon; competes with CVS Caremark Mail Service Pharmacy on 90-day maintenance medication fulfillment and represents a structural threat to traditional PBM-retail distribution economics.

Broad incumbents

• Walgreens Boots Alliance (Sycamore Partners): Major U.S. retail pharmacy chain now privately held by Sycamore Partners after its 2025 take-private; competes with CVS Pharmacy in the retail dispensing channel and serves as a network pharmacy partner to CVS Caremark — a relevant structural comparable given overlapping retail-pharmacy economics and Rite Aid transaction dynamics.
• Cigna Group (Evernorth): Health services parent that sold Express Scripts PBM to HCSC in 2025 but retains Evernorth specialty pharmacy, Accredo, and Express Scripts PBM services through transition; broadly comparable to CVS Health given integrated payer-PBM-pharmacy exposure even after the PBM divestiture.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CVS Caremark